Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques

[1]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[2]  M. Shoichet,et al.  Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-β in TgCRND8 mice. , 2013, ACS chemical neuroscience.

[3]  T. Bayer,et al.  Intraneuronal Aβ accumulation and neurodegeneration: lessons from transgenic models. , 2012, Life sciences.

[4]  R. Nitsch,et al.  Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation , 2012, Translational Psychiatry.

[5]  L. Breydo,et al.  Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice , 2012, Molecular Neurodegeneration.

[6]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[7]  D. Berlau,et al.  A population-based clinicopathological study in the oldest-old: the 90+ study. , 2012, Current Alzheimer research.

[8]  P. Fraering,et al.  Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified γ-Secretase Complexes , 2012, PloS one.

[9]  Hans-Ulrich Demuth,et al.  Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid , 2012, Nature.

[10]  J. Trojanowski,et al.  Intraneuronal APP, Not Free Aβ Peptides in 3xTg-AD Mice: Implications for Tau versus Aβ-Mediated Alzheimer Neurodegeneration , 2011, The Journal of Neuroscience.

[11]  N. Robakis.  Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives , 2011, Neurobiology of Aging.

[12]  M. Szyf,et al.  Transgenic mice as a model of pre-clinical Alzheimer's disease. , 2011, Current Alzheimer research.

[13]  J. Marsh,et al.  Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers , 2010, Molecular Neurodegeneration.

[14]  C. Glabe,et al.  Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.

[15]  R. Kayed,et al.  Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer* , 2009, Journal of Biological Chemistry.

[16]  C. Glabe,et al.  Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.

[17]  P. Zandi,et al.  No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies , 2008, Neurology.

[18]  B. Henriques-Normark,et al.  ETosis: A Novel Cell Death Pathway , 2008, Science Signaling.

[19]  Elizabeth Head,et al.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.

[20]  A. Levey,et al.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities , 2007, The EMBO journal.

[21]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[22]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[23]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[24]  H. Steinbusch,et al.  Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. , 2004, The American journal of pathology.

[25]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[28]  Brian J Cummings,et al.  Optimization of techniques for the maximal detection and quantification of Alzheimer’s-related neuropathology with digital imaging , 2002, Neurobiology of Aging.

[29]  P. A. Peterson,et al.  Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease , 2001, Histopathology.

[30]  Brian J Cummings,et al.  Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in alzheimer's disease , 1992, Neuroscience.

[31]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[32]  D. Selkoe,et al.  Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. , 1991, The American journal of pathology.

[33]  J. Trojanowski,et al.  Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Trojanowski,et al.  Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. , 1989, The American journal of pathology.

[35]  H. Wiśniewski,et al.  Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Selkoe,et al.  Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Brian J. Wiltgen,et al.  Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b , 2012 .

[38]  W. Klein,et al.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.

[39]  P. Greengard,et al.  Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.

[40]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[41]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[42]  W. Rosenblum.  The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. , 1997, Journal of neuropathology and experimental neurology.

[43]  P. Gambetti,et al.  Immunolocalization of the amyloid precursor protein within the senile plaque. , 1989, Progress in clinical and biological research.

[44]  G. Glenner,et al.  A study of the morphology and distribution of amyloid beta protein immunoreactive plaque and related lesions in the brains of Alzheimer's disease and adult Down's syndrome. , 1989, Progress in clinical and biological research.

[45]  G. Glenner,et al.  A study of the morphology and distribution of amyloid β protein immunoreactive plaque and related lesions in the brains of Alzheimer's disease and adult Down's syndrome , 1989 .